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Abstract 25 
Background: Treatment for opioid dependence in Ireland is provided predominantly by general 26 
practitioners (GP) who have undergone additional training in opioid agonist treatment (OAT) and 27 
substance misuse. The National Methadone Treatment Programme (MTP) was introduced in 1998, 28 
and was designed to treat the opioid dependent population and to regulate the prescribing regimes at 29 
the time. The past two decades have seen the increased prescribing of methadone in primary care and 30 
changes in type of opioid abused, in particular, the increased use of over the counter (OTC) and 31 
prescription medications. Despite the scaling up of OAT in Ireland, drug related deaths however have 32 
increased and waiting lists for treatment exist in some areas outside the capital, Dublin. Two previous 33 
MTP reviews have made recommendations aimed at improving and scaling up of OAT in Ireland. 34 
This study updates these recommendations and is the first time that a group of national experts have 35 
engaged in structured research to identify barriers to OAT delivery in Ireland. The aim was to explore 36 
the views of national statutory and non-statutory stakeholders and experts on current barriers within 37 
the MTP and broader OAT delivery structures in order to inform their future design and 38 
implementation.  39 
Methods: A single focus group with a chosen group of national key stakeholders and experts with a 40 
broad range of expertise (clinical, addiction and social inclusion management, harm reduction, 41 
homelessness, specialist GPs, academics) (n=11) was conducted.  The group included national 42 
representation from the areas of drug treatment delivery, service design, policy and practice in Ireland.  43 
Results: Four themes emerged from the narrative analysis, and centred on OAT Choices and Patient 44 
Characteristics; Systemic Barriers to Optimal OAT Service Provision; GP Training and Registration 45 
in the MTP, and Solutions and Models of Good Practice: Using What You Have. 46 
Conclusion: The study identified a series of improvement strategies which could reduce barriers to 47 
access and the stigma associated with OAT, optimise therapeutic choices, enhance interagency care 48 
planning within the MTP, utilise the strengths of community pharmacy and nurse prescribers, and 49 
recruit and support methadone prescribing GPs in Ireland. 50 
 51 
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Background 69 
Opioid dependence is a chronic, relapsing disorder with permanent metabolic deficiency [1], and 70 
characteristically complex in terms of patient care, pharmacological, psycho-social and relapse 71 
prevention modalities, and treatment outcomes [2, 3]. Ireland currently provides opioid agonist 72 
treatment (OAT) to those suffering from opioid dependence within a model of care which 73 
acknowledges the central role of the specialist trained general practitioner (GP) in primary care.  In 74 
Ireland OAT is commenced by suitably trained specialist (GPs) in either addiction clinics or general 75 
practice settings (Level 2 GP). Once the patient is stabilised on OAT, referral to Level 1 GPs working 76 
in the community for ongoing management can occur. Recent studies in 2013 and 2016 indicate a 77 
generally positive attitude of prescribing GPs toward methadone treatment. This was also underpinned 78 
by their belief that primary care prescribing of methadone is an essential service to drug users in the 79 
community, and one that supports a good relationship between the patient and GP [4, 5]. Prescribing 80 
GPs work closely with both statutory (funded and operated by the Health Services Executive, HSE) 81 
and non-statutory (part funded by the HSE through a service level agreement, SLA) organisations to 82 
optimise OAT delivery. Many of the non-statutory groups provide support and advocacy groups and a 83 
number of the larger agencies provide residential detoxification facilities. A number of the non-84 
statutory agencies have a national brief and have been pivotal in the expansion of harm reduction and 85 
OAT in Ireland. These groups have also advocated for the decriminalisation of drug use along with 86 
the setting up of drug consumption rooms. They play a key role in drug policy and advocate for 87 
prompt and easy access to OAT.  88 
In terms of OAT pharmacological options, substitution treatment using methadone is the most 89 
common formulation, with buprenorphine-naloxone currently available on a limited named patient 90 
basis only. Methadone has been available in Ireland since 1992, and was initially restricted in 91 
availability to the capital, Dublin. The ‘Report of the Expert Group on the Establishment of a Protocol 92 
for the Prescribing of Methadone’ was conducted in 1993. In 1998, the ‘Misuse of Drugs (Supervision 93 
of Prescription and Supply of Methadone) Regulations’ was set up and has since stipulated regulatory 94 
structures for treating opioid dependent patients  using methadone. The Methadone Treatment 95 
Programme (MTP) protocol designed in 1998 guides OAT treatment delivery in primary care, in 96 
5 
 
5 
 
terms of protocols for methadone prescribing, guidelines and standards for patient management and 97 
care, specialist training requirements for GPs, and protocols for clinical audit [6]. Several reviews of 98 
the MTP have been conducted, both internally in 2005 by the ‘Methadone Prescribing 99 
Implementation Committee’ itself and externally in 2010 [7]. These reviews recommended improved 100 
prescribing and quality of practice in both community and primary care, in order to optimise treatment 101 
reach and access across the country, and with support from inter-agency referral pathways. All 102 
patients on methadone are listed on the confidential Central Treatment List (CTL) with each patient 103 
linked to one specific prescriber and a single dispensing site.  104 
The Irish College of General Practitioners (ICGP) provides the specialist addiction training 105 
for GPs who prescribe OAT and plays a central role in the provision and auditing of the MTP. 106 
Training consists of an on-line training module in order to qualify for a Level 1 contract. A longer 107 
course consisting of workshops, on-line modules and a practice improvement project is required to 108 
obtain a Level 2 GP contract. Both Level 1 and Level 2 contracts attract additional remuneration for 109 
GPs looking after patients on OAT and ongoing audit of patient care is an essential requirement for 110 
maintenance of the contract.  Since 1998, the number of prescribing GPs has risen steadily each year 111 
and there are currently (mid 2017), a total of 345 Level 1 GPs and 57 Level 2 GPs providing OAT 112 
treatment in primary care. 113 
Since the introduction of the MTP greater prescribing of methadone in primary care is 114 
observed (Central Treatment List). As mentioned, during the early years of the MTP, heroin use and 115 
treatment were mainly confined to the capital, Dublin. In more recent times, the opioid misuse 116 
problem has spread to outside the capital, and regional OAT structures have struggled to meet the 117 
demand resulting in waiting lists in areas outside of Dublin. There have also been increasing drug 118 
related deaths and changes in the type of opioid abused (over the counter and prescription 119 
medications). Given that GPs currently provide the clear majority of OAT in Ireland across a variety 120 
of settings, the ICGP conducted a focus group study to investigate national stakeholder views around 121 
current provision of the MTP, barriers experienced and perspectives around how to improve its design 122 
and implementation in Ireland.  123 
  124 
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Methods 125 
Aim: The aim was to explore the views of national statutory and non-statutory stakeholders and 126 
experts on current barriers within the MTP and broader OAT framework in order to inform their 127 
future design and implementation. 128 
Approach A qualitative study using a single focus group with a purposive sample of national key 129 
stakeholders and experts, with a broad range of expertise (clinical, addiction and social inclusion 130 
management, harm reduction, homelessness, specialist GPs, academics) was conducted. The research 131 
team selected participants to ensure national representation. Seven of the eleven experts have a 132 
national brief to their roles and oversee OAT design and implementation across the entire country. 133 
Eight of the eleven participants participate at a national level in drug related policy. The participants 134 
were also selected to ensure that non-statutory agencies were adequately represented and that these 135 
groups had a national brief (n=3). The focus group was conducted in Dublin to facilitate the largest 136 
number of participants but teleconferencing facilities were made available to those unable to travel 137 
(n=3). A focus group guide using four broad questions (see Supplemental File) was designed by the 138 
team, which consisted of the Director and Assistant Director of the Substance Misuse Programme 139 
(SMP) at the ICGP, the Clinical Audit Facilitator (CAF), who is also an academic, and the 140 
administrator of the SMP. The guide explored the identification of patient, system and clinical barriers 141 
and enablers to accessing and engaging with OAT, immediate and long term solutions to enhancing 142 
OAT provisions in the community, and models of good practice and lessons learnt which could be 143 
shared nationally and incorporated into the revised MTP. 144 
Ethical and Study Procedure: Ethical approval was granted by the ICGP. Chosen stakeholders were 145 
sent an email with information around the focus group aims and objectives, procedures around 146 
anonymity and voluntary withdrawal assurances, and with an invitation to attend the focus group. The 147 
focus group took place at the ICGP premises in the Irish capital, Dublin. For non-attenders (n=2) 148 
teleconferencing facilities were made available All participants signed a consent form permitting 149 
audio-recording. The focus group was facilitated jointly by author one and author four. Following the 150 
focus group, the audio recording was transcribed and destroyed. All data in the transcript was 151 
anonymised.  152 
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Data Analysis: A content analysis of the data was undertaken by author one and two, which involved 153 
open, axial and selective coding resulting in the generation of listing of key concepts, ideas, words 154 
and phrases, formulating main and sub categories, and generating overarching themes.  155 
 156 
Results 157 
Both statutory (ST) and non-statutory agencies (NST) with a gender balance were represented (n=11). 158 
Six males and five females participated in the focus group, with four specialist GPs, four ST (funded 159 
and operated by the HSE) and three NST stakeholders (part funded by the HSE through an SLA) 160 
represented. Four themes emerged from the analysis of narratives, and are presented here with 161 
illustrative quotes.  162 
 163 
OAT Choices and Patient Characteristics 164 
Initial discussions centred on the stigma toward OAT in Ireland, and the general public and drug 165 
users’ negative attitude towards it. Comments were made around the lack of choice in OAT in Ireland, 166 
with methadone available nationally for the majority of patients and buprenorphine-naloxone (trade 167 
name Suboxone) restricted to specific patient cohorts. In contrast to the stigma attached to methadone, 168 
patients appeared to have more favourable attitudes with regard to Suboxone, which is seen as a 169 
medical treatment.  170 
‘We need to have Buprenorphine available through the pharmacies nationally and not to 171 
prohibit its use.’ [SpGP1] 172 
Additional changing patterns in opioid drug abuse were observed by the group, with a shift toward 173 
increased dependence on prescription and over the counter opioid based analgesics. These changing 174 
OAT patient characteristics in terms of those with presenting with prescription and OTC opioid abuse 175 
(as opposed to heroin), and the difficulties for such patients given the stigma and location in accessing 176 
mainstream addiction clinics which generally treat heroin addiction were discussed and central to the 177 
requirement to expand choice in OAT.  178 
‘Patterns are changing, over the counter painkillers, reduction in heroin users but our 179 
models of treatment haven’t changed accordingly.’ [SpGP1]  180 
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Concerns were voiced around issue of OAT patient co-dependence on other substances generally 181 
alcohol, and benzodiazepines and Z-hypnotics, both prescribed and sourced on the street. Participants 182 
described difficulties in management of these poly dependencies. National assessment, referral and 183 
detoxification pathways for benzodiazepine and Z-hypnotic drug abuse and dependence were 184 
described as lacking. Efforts to manage the problem centred on some service providers refusing to 185 
prescribe these drugs to their methadone patients. Patients were described as circumventing this by 186 
accessing a GP other than their methadone prescriber.  187 
 ‘One of the things that puts GPs off even though it is not directly related to methadone 188 
it’s a whole big mess of benzo and tablet problems.’ [SpGP3] 189 
Behavioural issues due to poly substance intoxication was also viewed as problematic for primary 190 
care and community pharmacy staff who dispense methadone, and at times requiring security 191 
measures. 192 
‘There is a problem particularly for pharmacies as well as GPs…pharmacies are a 193 
business and they can’t afford to have someone coming in and causing chaos in a 194 
pharmacy’[SpGP2] 195 
Some problems are evident with regard to all female GP practices and the supervision of drug 196 
screening for male methadone patients.  197 
‘We have no men in our practice at the moment. So supervising men is a problem for us’. 198 
[SpGP3] 199 
Long term methadone patients along with the aging methadone patient population were viewed as 200 
creating a draw on services.  Discussions centred on the adaptation of service models given the aging 201 
population of both drug users and methadone patients. 202 
‘We have to recognise it is an ageing model and in Dublin…I think we need to be very 203 
careful about setting up new models that are potentially very expensive for a profile that 204 
may not exist in 10 or 15 years time.’ [SpGP1] 205 
Participants described the complexities of treating and engaging with homeless drug users, and the 206 
difficulties around long term methadone treatment. In terms of attempting to reduce patients and taper 207 
off methadone, participants described the need for a broader de-medicalised approach to recovery. 208 
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Debate occurred with regard to the Irish stipulation for opioid free urines prior to accessing a 209 
detoxification centre.  210 
‘People have to have 3 or 4 urines that are opioid-free before they can be admitted to a 211 
centre…if they are able to manage 3 or 4 urines that are opioid-free then they don’t need 212 
to go into the detox centre in the first place...’ [NS2] 213 
 214 
Systemic Barriers to Optimal OAT Service Provision 215 
National provision of OAT and dispensing of methadone was described as patchy, and largely 216 
concentrated in the capital, Dublin, and larger urban areas. Some participants voiced concern around 217 
the need for more Health Service Executive dispensing centres as a way of dealing with national 218 
demand, particularly in the context of destabilisation of patients and the current requirement to resume 219 
initiation of treatment in the clinics. Other logistical complexities for patients centred on lack of rural 220 
GPs and community pharmacies willing to prescribe and dispense methadone, rural residences and 221 
cost of transport, particularly outside of the capital. As outlined in the previous theme, stigma of 222 
methadone, and the lack of choice with large methadone clinics in some areas offering the only route 223 
to treatment were viewed as representing fundamental systemic barriers to OAT access. Service level 224 
barriers to access for individuals experiencing opioid dependence were described as centring on the 225 
complexities around the patients address of residence with regard to options to access stabilisation 226 
OAT in clinics or by a Level 2 GP, their general preferences to attend primary care for OAT, and lack 227 
of availability of Level 2 GPs in the community. Many participants described long waiting lists and 228 
under capacity of local services to deal with the issue of opioid dependence, and provide the current 229 
requirement for regularity of consultations. 230 
‘There is a problem with waiting lists and I think nationally there needs to be a more 231 
robust, systematic review of waiting lists and if a patient is waiting for more than 3 232 
months for treatment there needs to be a proper analysis’. [SpGP1] 233 
 ‘If there were more Methadone prescribers within the GP community then there would 234 
be no need for these people there in the country to travel to access treatment’. [NS2] 235 
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Other blocks centred on homeless patients seeking treatment with no fixed address, and the treatment 236 
influx from parts of the country outside the capital. 237 
‘Where are the homeless people going? This is not a good model of care. Having them 238 
sent to multiple pharmacies and multiple centres causes violence and antisocial 239 
behaviour, and in fact you are creating more problems and the treatment is bringing 240 
problems with it.’ [SpGP1] 241 
The MTP given its stipulation to stabilise patients in addiction clinics or by Level 2 GPs prior to 242 
referral to the community Level 1 GP was viewed as not operating efficiently. The restriction of 243 
numbers of patients managed by Level 1 GP (n=15) in the community was central to this issue and 244 
was viewed as contributing to long waiting lists. 245 
‘Information we are getting is that everybody and everything has to go through the 246 
clinic…we have Level 2 GPs… I would be saying why are we not utilising the L2 GPs to 247 
the max and not be creating waiting lists.’ [SpGP4] 248 
GP Training and Registration in the MTP 249 
Participants discussed the specialist Level 1 and 2 training and Health Service Executive registration 250 
complexities as systemic barriers to providing optimal OAT in Ireland. Stigma of OAT within 251 
medical practice and education was viewed as affecting training uptake. Those involved in GP 252 
training (and who prescribe methadone) described the willingness of younger doctors to engage in 253 
training when exposed to OAT, and particularly when hosted by larger GP practices involved in 254 
methadone prescribing. GP registrars not exposed to the opioid dependent patient cohort were 255 
described as not willing, and similar was described with regard to newly qualified pharmacists.  256 
‘You would like to think that GP trainers would be the frontline for educating people 257 
being open to the idea that all patients are equal…… the majority of GP trainers that we 258 
have do not do methadone and would not entertain methadone treatment. There are 259 
messages like that going out to trainees’ [SpGP4] 260 
Difficulties centred on the lack of uniform approach to mentoring younger GPs, and the current 261 
requirement for methadone contracts to be assigned to a practice address, not the prescriber. The 262 
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Level 1 and Level 2 structures were viewed as complex and difficult, particularly for newly qualified 263 
GPs entering employment and securing employment in primary care practices not part of the MTP.   264 
‘It is an incredible missed opportunity, every GP trainee in the country should be obliged 265 
to do Methadone training like they are obliged to do the Women’s Health. [SpGP3] 266 
Another systemic issue in the MTP was described as centring on the significant effort, organisation 267 
and commitment in the contractual difficulties to become and register as a Level 2 prescriber which 268 
was viewed as deterring some Level 1 GPs from progressing. 269 
‘Its too difficult to get to a Level 2 scenario…if you have done the Level 1 training,  to 270 
get to a Level 2 prescriber is too difficult. It’s a long process.’ [SpGP2] 271 
Complexities of the GPs role in supporting the opioid dependent patient were discussed in terms of 272 
length of patient consultation, the myriad of additional health conditions and social challenges. In 273 
some areas Level 1 GPs were under resourced despite the funding allocation for OAT patients, and 274 
unable and not willing to take on more complex patients.  275 
‘Methadone is well remunerated... I don’t begrudge any of our methadone users the time 276 
they take up. But new GPs won’t start because it’s so complicated,’[SpGP3] 277 
 278 
Solutions and Models of Good Practice: Using What You Have 279 
Firstly, participants discussed potential solutions and best practices for shared learning. Several key 280 
areas were identified, with first centring on the requirement for all GP registrars to be trained in 281 
methadone prescribing and the treatment of opioid dependence and related health problems. The 282 
ICGP has long held the view that all GPs should be in a position to provide methadone and other 283 
opioid agonist treatment in primary care ‘to be part of routine GP primary care’. Encouraging GPs to 284 
change attitudes, and engage in the specialist training via mentoring of more experienced GPs was 285 
discussed, and appeared to represent a way of reducing fears and concerns around engaging with the 286 
methadone patient cohort. 287 
‘I’d like to see that Level 2 would become more specialised and that Level 1 would 288 
almost become normal for GPs so that they have facilities for benzos and for other 289 
addictions.’[SpGP2] 290 
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Secondly, the group discussed how to optimise the available resources within the current MTP. 291 
Finding ways for supporting OAT patients via shared care planning with available community 292 
agencies was viewed as vital within the MTP. Addiction clinics were viewed as having a range of 293 
supports available to patients. Avenues for potential support for community practitioners centred on 294 
the available outreach, social, community and psychological support services, and engaging with case 295 
workers from local Drug Task Forces.  296 
‘There is a perception among GPs like me who are doing methadone versus the clinics is 297 
that the clinics have a lot of services that we don’t get so easily, like the counselling 298 
services, …if you were able to offer GPs some of those supports…once a month or 299 
something like that, that would be just as good as having a full blown clinic’. [SpGP3] 300 
Informal meetings between staff were viewed as important to help share issues and support each other 301 
within the practice, particularly if GPs were working part time.  302 
‘The work is too complex to be able to manage it on your own’. [SpGP3] 303 
‘We tend to be the key worker, because we are the only person that these people are 304 
seeing.’[SpGP1]. 305 
 306 
Using family support systems where possible from treatment onset was also viewed as a potential 307 
lesson learnt. Complexities arise when patients have no family or are homeless. Shared care and key 308 
working was viewed as very important. 309 
‘Resources out there that are probably underutilized at the moment…for example, 310 
voluntary based services around the corner from the GP. It is about getting to know the 311 
person. It is about case management in all areas of their life.’ [NS1] 312 
Thirdly, given the logistical barriers for patients in rural areas, or areas with no Level 2 GP, the group 313 
discussed the potentials for utilising community pharmacy and nurse prescribing in the community. 314 
Complexities centred on this recommendation, and current service level agreements.   315 
‘I would see a lot of what’s done by the doctor, could be done by the nurses…and the 316 
doctor then can be able to prescribe more …and be able to look after more in terms of 317 
the monitoring, the supervision, the diagnosis of mental illness.’[SpGP1]. 318 
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Lastly, the remit of community pharmacy could expand to support work in primary care in terms of 319 
extended dispensing, education and vaccination of drug users. Community pharmacies could expand 320 
to take on the role of patient vaccination (Hepatitis A and B) within their role in providing needle and 321 
syringe exchange. 322 
‘Another job that pharmacists might take on is Hepatitis A & B vaccination in 323 
pharmacies. It’s not an immediately practical thing but something definitely to think of in 324 
the future’. [SpGP2] 325 
‘Down the country, why not augment the community pharmacies with extra staff. The 7 326 
day pharmacies that are open.’[SpGP1] 327 
 328 
Discussion 329 
The study illustrates the complexities around the MTP within primary care in Ireland, along with the 330 
systemic failures in optimal service provision for opioid dependent individuals, and challenges 331 
encountered in managing opioid drug users.  Primary care providers can take a proactive role in 332 
treatment of opioid dependence [8,9,10] and so enhance health care provision [11,12] . Integration of 333 
OAT into primary care via different models can expand access to treatment [13]. Mainstreaming of 334 
OAT into primary care can also help to reduce stigma as a barrier to treatment uptake [14, 15]. 335 
Systemic barriers observed by these national stakeholders and experts in Ireland were similar to those 336 
reported elsewhere and centre on stigma, lack of therapeutic choice in Ireland, reluctance of GPs to 337 
prescribe OAT, and complex reimbursement systems [16, 17, 18, 19, 20, 21]. Lack of MTP coverage 338 
across the country was illustrated and represents a systemic barrier to access for patients living in 339 
rural areas, homeless patients without a residential address, and those seeking treatment due to long 340 
waiting lists. Similar issues have been reported in other countries exploring the expansion of OAT 341 
into community and primary care [13, 21, 22]. The expansion of buprenorphine-naloxone availability 342 
could overcome this barrier. In many jurisdictions buprenorphine-naloxone availability in primary 343 
care has allowed for the rapid expansion of OAT. Buprenorphine’s use as a combined product with 344 
naloxone has allowed for a safe reduction in supervision requirements and increased utility in patients 345 
living in isolated areas with poor access to medical and pharmacy services. The use of tele-medicine 346 
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linking less experienced rural GPs with their more specialist colleagues could further increase OAT 347 
coverage nationally.  348 
Participants described the complexities of the current Irish opioid dependent population in 349 
terms of long term and aging patients, co-dependencies on other drugs such as benzodiazepines and 350 
Z-hypnotics, abuse of prescription and OTC opioid analgesics, and homelessness. These complexities 351 
of opioid dependent patients in terms of psychiatric co-morbidity, and co- dependencies are well 352 
evidenced in the literature [10]. Similar to other countries, primary care practice based pressures 353 
centre on patient behavioural issues and resources required to support longer consultation times due to 354 
the health and social care challenges of these patients.  Studies have reported on GP reluctance to 355 
prescribe methadone due to their fears around patient behavioural issues, the complexities of opioid 356 
dependent patients, concerns around workload and the time required to manage such patients, and 357 
staff safety [4, 6, 16, 17, 23, 24, 25, 26, 27, 28, 29].  Van Hout and Bingham [4] have underscored the 358 
multiplicity of roles (patient advocate, medical supervisor and detoxification gate keeper) that GPs 359 
have when involved in prescribing methadone. 360 
Strategies to address systemic barriers centre on the expansion of training, increased use of 361 
community pharmacists,  development of  the nurse prescribing role and promoting the easy access to 362 
GPs via key working [13]. Shared care with available community based services was viewed as vital 363 
in terms of family support, key working, outreach and psycho-social support. The lack of therapeutic 364 
choice in Ireland needs to be addressed. Buprenorphine is underutilised in Ireland due its restricted 365 
availability, but has been reported as safe and effective in OAT in primary care [21]. Providing this 366 
OAT option could lessen the draw on resources and support OAT patients across the country. Other 367 
potential solutions using the available resources in the MTP centred on expanding the remit of the 368 
community pharmacy in terms of patient education and vaccination, and the role of the nurse 369 
prescriber. Nurse prescribers can overcome systemic barriers and failures and improve access to OAT 370 
[21]. Technology using E-consultation and e-prescribing to support patients who have to travel long 371 
distances for treatment could also be considered and would facilitate access to Level 2 GP services. 372 
Similar to research in the United States [10] and building on the primary care model now 373 
widely accepted in Europe, mainstreaming of OAT has many advantages, and success will depend on 374 
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service delivery models and the improved and expanding training of doctors in Ireland. GPs are 375 
ideally placed to diagnose patients with substance related problems and require a specific skill set to 376 
provide clinical care.  The focus group highlighted the need to ensure newly qualified GPs are trained 377 
in OAT and to support those interested in securing Level 1 and Level 2 contracts. Participants echoed 378 
views reported by the ICGP in 2016, where a need for continued support of prescribing GPs (Level 1 379 
and 2), training of new GPs and encouragement of further specialisation to Level 2 were identified 380 
[5]. Issues around encouraging newly qualified GPs to engage in provision of the MTP service were 381 
described, and support research reporting on newly qualified GPs having a more positive attitude 382 
toward opioid dependent patients and self-awareness of competencies to treat this condition [30, 31]. 383 
Training at undergraduate and registrar levels is warranted [10]. No Irish medical school has any 384 
elective or integrated training in addictions, and with no documented drug and alcohol teaching 385 
sessions [32, 33].  Particularly in undergraduate training, addiction as a disease should be integrated 386 
into pre-clinical course material, and careful emphasis on development of positive attitudes to 387 
working with addicted patients is warranted [34, 35, 36]. Hussein Rassool [37] has indicated that 388 
substance misuse training can contribute to an increase in confidence in participants in working with 389 
substance misusing patients.  Research elsewhere has underscored the need to integrate addiction 390 
medicine into medical and primary care registrar education, given the public health cost of medical, 391 
behavioural and social problems associated with substance use, and also given the frequent lack of 392 
recognition of substance abuse and failure to provide appropriate treatment on the part of general 393 
practitioners [38, 39, 40, 41, 42, 43].  394 
The use of the focus group methodology in this study allowed for the efficient collection of 395 
the views of a very diverse group of Irish addiction experts in relation to the blocks and facilitators to 396 
OAT in Ireland. The inclusion of both statutory and non-statutory experts allowed for robust and 397 
insightful discussion and the focus group methodology is recognised as a good research method to 398 
capture the richness of these discussions. The inclusion of experts in the area of policy development 399 
and implementation along with experts in treatment design and delivery allowed for an in-depth 400 
exploration of the issues. 401 
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There are a number of limitations to this study. The findings are limited to the data collected 402 
from only one focus group which contained only 11 experts. While the research team endeavoured to 403 
ensure national representation it is reasonable to assume that this group is not fully representative of 404 
all regions and there are deficits in recognising all the barriers and enablers to OAT in Ireland. The 405 
focus group did not include patients or patient representatives.  A further limitation is that the focus 406 
group was conducted by, or included, those who have responsibility for the SMP. The researchers 407 
recognised this and attempted to limit this conflict of interest by picking researcher 1 as the group 408 
facilitator. This researcher would have had the least prior involvement with the focus group 409 
participants. Lastly, the involvement of the members of the SMP in the focus group may have 410 
impacted on participants’ willingness to share their views fully for fear of antagonising or upsetting 411 
these SMP members.  412 
 413 
Conclusion 414 
The study is a first step in a process to identify barriers to optimal OAT provision by GPs in Ireland. It 415 
has successfully identified a number of previously unrecognised issues that will be progressed through 416 
a number of national drug treatment and policy groups. Key national stakeholders and experts 417 
identified a series of improvement strategies which can reduce OAT stigma and barriers to access, 418 
optimise therapeutic choice, enhance interagency care planning within the MTP, utilise the strengths 419 
of community pharmacy and nurse prescribers, and recruit and support methadone prescribing GPs. 420 
The ICGP will advance the implementation of these recommendations through a number of national 421 
drug treatment and policy groups and will plan and undertake a series of independently run expert 422 
focus groups across the country to gain further insight into this topic and add to these 423 
recommendations.  424 
 425 
 426 
 427 
 428 
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